Drug maker Bristol-Myers Squibb to buy Celgene in $74bn deal
New York-based pharmaceutical giant Bristol-Myers Squibb on Thursday announced it would buy US biotech firm Celgene in a $74 billion cash-and-stock deal, creating a rival to the world's largest drug makers.